Therapeutic targeting of the hypoxic tumour microenvironment
Hypoxia is prevalent in human tumours and contributes to microenvironments that shape
cancer evolution and adversely affect therapeutic outcomes. Historically, two different …
cancer evolution and adversely affect therapeutic outcomes. Historically, two different …
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
U Majeed, R Manochakian, Y Zhao, Y Lou - Journal of hematology & …, 2021 - Springer
Lung cancer remains the leading cause of cancer-related mortality in both men and women
in the US and worldwide. Non-small cell lung cancer is the most common variety accounting …
in the US and worldwide. Non-small cell lung cancer is the most common variety accounting …
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Protein tyrosine kinases of the human epidermal growth factor receptor family, including
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
Mobocertinib, an oral epidermal growth factor receptor (EGFR) inhibitor targeting EGFR
gene mutations, including exon 20 insertions (EGFR ex20ins), in non–small cell lung …
gene mutations, including exon 20 insertions (EGFR ex20ins), in non–small cell lung …
[HTML][HTML] Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 …
M Riudavets, I Sullivan, P Abdayem, D Planchard - ESMO open, 2021 - Elsevier
Non-small-cell lung cancer (NSCLC) harbouring HER2 alterations is now considered a
distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms …
distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms …
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer
F Gonzalvez, S Vincent, TE Baker, AE Gould, S Li… - Cancer Discovery, 2021 - AACR
Most EGFR exon 20 insertion (EGFR ex20ins) driver mutations in non–small cell lung
cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To …
cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To …
Targeting EGFR Exon 20 Insertions in Non–Small Cell Lung Cancer: Recent Advances and Clinical Updates
CB Meador, LV Sequist, Z Piotrowska - Cancer discovery, 2021 - AACR
Approximately 10% of EGFR-activating mutations occur as in-frame insertion mutations in
exon 20 of the EGFR kinase domain (EGFR ins20). EGFR ins20 mutations have not …
exon 20 of the EGFR kinase domain (EGFR ins20). EGFR ins20 mutations have not …
Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations
D Koenig, S Savic Prince, SI Rothschild - Cancers, 2021 - mdpi.com
Simple Summary The treatment of advanced and metastatic non-small cell lung cancer
(NSCLC) has changed dramatically in recent years due to advanced molecular diagnostics …
(NSCLC) has changed dramatically in recent years due to advanced molecular diagnostics …
Tumour hypoxia-mediated immunosuppression: mechanisms and therapeutic approaches to improve cancer immunotherapy
The magnitude of the host immune response can be regulated by either stimulatory or
inhibitory immune checkpoint molecules. Receptor-ligand binding between inhibitory …
inhibitory immune checkpoint molecules. Receptor-ligand binding between inhibitory …
Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review
Objectives The burden of epidermal growth factor receptor (EGFR) exon 20 insertion
mutation (Exon 20ins) in non-small cell lung cancer is not well understood. A systematic …
mutation (Exon 20ins) in non-small cell lung cancer is not well understood. A systematic …